The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
申请人:AstraZeneca AB
公开号:US07947676B2
公开(公告)日:2011-05-24
The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors
作者:Richard Ducray、Peter Ballard、Bernard C. Barlaam、Mark D. Hickinson、Jason G. Kettle、Donald J. Ogilvie、Catherine B. Trigwell
DOI:10.1016/j.bmcl.2007.12.035
日期:2008.2
Novel 4-anilino-1H-pyrazolo[3,4-d]pyrimidines have been synthesized and evaluated in vitro for erbB2 and EGFR kinase inhibition. A representative compound displaying oral bioavailability in rat and dog illustrates the potential of this series to provide orally active erbB2 inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.